Search results for "Intravenou"

showing 10 items of 390 documents

Chromatic-achromatic perimetry in four clinic cases: Glaucoma and diabetes

2015

Color perimetry has interesting clinical application for the diagnosis and detection of certain eye conditions, due to the variations that certain diseases can cause in chromatic thresholds, both in the red-green (RG) and the blue-yellow (BY) pathways.[1,2,3,4] The separate study of the visual function of both the chromatic and achromatic mechanisms could be more efficient in detecting sensitivity variations, and such variations would not be obscured by the intrusion of other mechanisms. Currently, the supply of conventional perimeters that are capable of performing a chromatic perimetry test is very limited and with reduced options regarding the possibility of choosing the physical charact…

Maleretinakoniohemangioblastomagenetic structuresComputer sciencemelanocytosisGlaucomaretinal vasoproliferative tumorEyeTwo stageslaw.inventionintra-arterial chemotherapyretinal capillary hemangiomaIntrusionlcsh:Ophthalmologylawperiocular chemotherapyintravitreal chemotherapytreatmentdiabetesenhanced depth imagingDiabetesenhanced depth imaging optical coherence tomographyMiddle AgedhemangiomaAchromatic lensFemaleOriginal Articleuveal melanomanevusAdulttumorchoroidal hemangiomaCiliary bodymonosomy 3lymphomaStimulus (physiology)Color spaceAutoflouroscenceuvearetinoblastomaContrast SensitivityosteomaCavernous hemangiomaParvoMagnoResearch basedmedicinemelanomagene expression profilingHumansmetastasisChemotherapyChromatic scalemetastasesirisÓpticachromatic perimetryoptical coherence tomographyintravenous chemotherapybusiness.industryChoroidKonioSubtenon′s chemotherapyReproducibility of ResultsPattern recognitionGlaucomamedicine.diseaseAchromatic perimetrymagnoOphthalmologyglaucomaDiabetes Mellitus Type 2lcsh:RE1-994parvoOptometryVisual Field TestsAstrocytic hamartomavitreous seedsArtificial intelligenceprognosisVisual FieldsbusinessChromatic perimetrymalignancy
researchProduct

Inhalational or intravenous anesthetics for craniotomies? Pro inhalational.

2006

In neurosurgery, anesthesiologists and surgeons focus on the same target - the brain. The nature of anesthetics is to interact with brain physiology, leading to favorable and adverse effects. Research in neuroanesthesia over the last three decades has been dedicated to identifying the optimal anesthetic agent to maintain coupling between cerebral blood flow and metabolism, keep cerebrovascular autoregulation intact, and not increase cerebral blood volume and intracranial pressure.Sevoflurane is less vasoactive than halothane, enflurane, isoflurane, or desflurane. The context sensitive half-life is short and similar to that of desflurane, which translates into fast on and offset. Compared wi…

Methyl Ethersmedicine.medical_specialtyIntracranial PressureMEDLINESevofluraneCardiovascular Physiological PhenomenaSevofluraneMedicineHomeostasisHumansAdverse effectPropofolMonitoring PhysiologicEpilepsybusiness.industryPatient SelectionIntravenous AnestheticsBrainElectroencephalographyAnesthesiology and Pain MedicineNeuroprotective AgentsAnesthesiaCerebrovascular CirculationAnesthesia Recovery PeriodAnesthetics InhalationPostoperative Nausea and VomitingNeurosurgeryAnesthesia Recovery PeriodbusinessAnesthetics IntravenousCraniotomymedicine.drugCurrent opinion in anaesthesiology
researchProduct

Fluconazole concentrations in pulmonary tissue and pericardial fluid

1997

In order to investigate the clinical efficacy of the triazole antifungal agent fluconazole (FCA) in the treatment of pulmonary mycosis, in the present study the concentrations of fluconazole in human pulmonary tissue, pericardial fluid and serum were determined at 1, 2, 12 and 13 h after intravenous administration of fluconazole 200 mg. The mean FCA concentrations in the serum were 4.04 mg/l (1 h), 3.82 mg/l (2 h), 2.35 mg/l (12 h) and 2.13 mg/l (13 h). The respective FCA levels in the pulmonary tissue were 4.64 mg/kg, 4.54 mg/kg; 3.50 mg/kg and 3.40 mg/kg and the concentrations in the pericardial fluid were 3.86 mg/l, 3.57 mg/l, 2.35 mg/l and 2.13 mg/l. The FCA concentrations in the pulmon…

Microbiology (medical)Antifungal AgentsMetabolic Clearance Ratemedicine.medical_treatmentTriazoleBiological AvailabilityPharmacologyPericardial Effusionchemistry.chemical_compoundPharmacokineticsCricetinaemedicineAnimalsHumansPericardiumInfusions IntravenousFluconazoleLungMycosisChemotherapyLungbusiness.industryPericardial fluidGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structurechemistryAnesthesiabusinessFluconazolemedicine.drugInfection
researchProduct

In vivo effects of intravascularly applied Escherichia coli hemolysin: dissociation between induction of granulocytopenia and lethality in monkeys.

1993

The effects of intravascular application of endotoxin-depleted Escherichia coli hemolysin (HlyA) was studied in rabbits and monkeys. In rabbits, bolus application of HlyA calculated to effect final blood levels of approximately 2-3 HU/ml (200-300 ng/ml) caused an acute fall of polymorphonuclear blood leukocytes to less than 20% of starting levels within 5 min. Additionally, platelet counts dropped to approximately 30% of starting levels, whereas lymphocyte counts varied considerably and seldom fell to less than 50%. Nine out ten animals that received 2-4 HU/ml toxin died within 90 min post application. These animals presented with signs of acute respiratory failure and post mortem inspectio…

Microbiology (medical)Blood Plateletsmedicine.medical_specialtyPathologyLymphocyteImmunologyBacterial ToxinsSpleenBlood PressurePulmonary EdemaBiologyPulmonary sequestrationLethal Dose 50Hemolysin ProteinsBacterial ProteinsIn vivoInternal medicinemedicineEscherichia coliImmunology and AllergyAnimalsLungLeukopeniaLungDose-Response Relationship DrugPancreatic ElastaseEscherichia coli ProteinsElastaseGeneral Medicinemedicine.diseasePulmonary edemaBlood Cell CountCapillariesMacaca fascicularisEndocrinologymedicine.anatomical_structureInjections Intra-ArterialLiverInjections IntravenousRabbitsmedicine.symptomSpleenAgranulocytosisGranulocytesMedical microbiology and immunology
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct

Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies

1989

Abstract The response of two patients with autoantibody-mediated C1-inhibitor (C1-INH) deficiency to replacement therapy with C1-INH was studied over a period of 3 d. In patient 1 an acute attack of angioedema was successfully managed by infusion of 1,000 U of C1-INH concentrate. C1-INH function returned to normal levels within 30 min, while CH50 and C4 peaked after 6-7 h and C1 hemolytic activity reached 50-60% of normal after 3 d. Immediately after the injection an increase in C1-INH-anti-C1-INH complexes was observed. Based on NH2-terminal sequence analysis of the patients' Mr 96,000 C1-INH, it is concluded that this fragment is generated after cleavage of C1-INH in its active site by on…

Molecular Sequence DataPharmacologyComplement C1 Inactivator ProteinsEpitopeC1-inhibitorAutoimmune DiseasesAntibody SpecificityImmunopathologyBlood plasmamedicineHumansheterocyclic compoundsAmino Acid SequenceAngioedemaInfusions IntravenousAutoantibodiesAngioedemabiologybusiness.industryAutoantibodyAntibody titerGeneral Medicinebiochemical phenomena metabolism and nutritionrespiratory systembacterial infections and mycosesrespiratory tract diseasesImmunologybiology.proteinmedicine.symptomAntibodybusinessResearch Article
researchProduct

Intravenous Busulfan for Autologous Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: a Survey of 952 Patients on Behalf of th…

2014

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67 +/- 2%, 53 +/- 2%, and 40 +/- 2%, respectively. The non-relapse mortality rate at 2 years was 7 +/- 1%. Five patients died from ve…

MyeloidMale[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyBone Marrow Transplantation/mortalitymedicine.medical_treatmentLeukemia Myeloid Acute/therapyHematopoietic stem cell transplantationAntineoplastic Agents Alkylating/administration & dosageLeukemia Myeloid Acute/mortalityGastroenterologyHSAC ONCAutologous stem-cell transplantationHematopoietic Stem Cell Transplantation/mortalityInfusions IntravenousBone Marrow TransplantationAcute leukemiaSurvival Rate/trendsTransplantation Autologous/mortalityLeukemiaData CollectionHematopoietic Stem Cell Transplantation[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedAlkylating3. Good healthEuropeSurvival RateLeukemia Myeloid AcuteLeukemiaFemaleIntravenousAutologousmedicine.drugAdultBusulfan/administration & dosageInfusionsmedicine.medical_specialtyAdolescentCyclophosphamideAntineoplastic AgentsAcuteTransplantation AutologousEurope/epidemiologyData Collection/methodsYoung AdultInternal medicinemedicineHumansAntineoplastic Agents AlkylatingBusulfanSurvival rateAgedRetrospective StudiesTransplantationbusiness.industrySettore MED/15medicine.diseaseTransplantationAdolescent; Adult; Aged; Antineoplastic Agents Alkylating; Bone Marrow Transplantation; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions Intravenous; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Autologous; Young Adult; Data CollectionImmunologybusinessBusulfan
researchProduct

Subcutaneous Veins Depth Estimation Method Using Monte Carlo Simulations

2015

International audience; Subcutaneous veins localization is basic and important step for any intravenous medication administration. Due to different physiological characteristics, mainly darker skin tone, scars or dehydrated condition of patients, medical staff face difficulty in veins localization. Through near infrared imaging technology the veins can be visualized due to high contrast between veins and skin tissue in this modality. Information on the depth of veins is equally important for proper catheterization or venipuncture procedures. Patients have different veins depth due to the different amount of fat present in the subcutaneous layer. The depth of veins from the skin surface cann…

Near InfraredMedical staffMonte Carlo methodSkin toneDiffused Reflectance01 natural sciences030218 nuclear medicine & medical imaging010309 optics03 medical and health sciences0302 clinical medicineSubcutaneous Veins0103 physical sciencesSkin surfaceMedical imagingMedicine[ SDV.IB ] Life Sciences [q-bio]/BioengineeringMonte CarloHigh contrastbusiness.industryMedication administrationReflectivity3. Good healthIntravenous (IV) Catheterizationcardiovascular system[SDV.IB]Life Sciences [q-bio]/BioengineeringbusinessBiomedical engineering
researchProduct

Treatment of metastatic breast cancer with vinorelbine and docetaxel.

2006

Objective: A phase II study was performed to evaluate efficacy and safety of the combination vinorelbine and docetaxel in patients with metastatic breast cancer previously treated with anthracycline-based regimens. Overall 41 patients were included in the study. Methods: Treatment consisted of vinorelbine 25 mg/m 2 and docetaxel 75 mg/m 2 , both administered on day 1 every 3 weeks for a maximum of 9 cycles. Most patients (92%) were postmenopausal with a median age of 57 years, and median ECOG performance of 1. Sites of disease were viscera in 42% of patients, bones in 30%, soft-tissues in 32%. Sixty-five percent of patients had >2 metastatic sites. Previous treatments included neo-adjuvant …

OncologyAdultCancer Researchmedicine.medical_specialtyDocetaxel; Metastatic breast cancer; VinorelbineAnthracyclinemedicine.medical_treatmentPhases of clinical researchBreast NeoplasmsDocetaxelNeutropeniaVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMucositisMedicineHumansInfusions IntravenousChemotherapybusiness.industryVinorelbineMiddle Agedmedicine.diseaseMetastatic breast cancerMetastatic breast cancerSurvival AnalysisTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessmedicine.drugAmerican journal of clinical oncology
researchProduct

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

2015

Aim To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods A 17-item anonymous questionnaire including 7 general and 10 investigational questions with free-text, single-choice, or multiple-choice answers was administered. Analysis of response distribution according to predefined factors was described by summary measures and conducted by χ2 test and other nonparametric tests. Results From January to June 2010, 581 patients completed the questionnaire; data of 404 patients constituted the final study sample. Three groups could be distinguished according to treatment: IV …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOral chemotherapyAdministration OralWork commitment03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImpact on family030212 general & internal medicineInfusions IntravenousOral therapyAgedbusiness.industryIntravenous chemotherapyGeneral MedicineMiddle AgedPatient perceptionsOncologyItaly030220 oncology & carcinogenesisQuality of LifeCombined therapyFemalebusinessTumori
researchProduct